• 69.2k views

Biosimilars and Cancer Supportive Care

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing approved reference biologic drug. In cancer supportive care, biosimilars have become increasingly important for managing various aspects of cancer treatment, including supportive therapies. One significant application of biosimilars in cancer supportive care is in the management of chemotherapy-induced neutropenia. Neutropenia, characterized by low levels of neutrophils (a type of white blood cell), is a common side effect of chemotherapy that can increase the risk of infections. Biosimilar versions of granulocyte colony-stimulating factors (G-CSFs), such as filgrastim and pegfilgrastim, are used to stimulate the production of neutrophils and reduce the duration and severity of neutropenia.

About the Speaker

Dr. Abdul Rahman Agha El Kinge Profile Image

Dr. Abdul Rahman Agha El Kinge

HOD Hematology Oncology, Fakeeh University Hospital, DXB

Upcoming Case Discussions

Leave a Comment

Your email address will not be published.

Author Post

authorimage

Impact

+

Talks

+

webinar

+

no.of registrations

One liner about speaker

Why is speaker relevant?

Dr. Abdul Rahman Agha El Kinge's Talks on Assimilate

webinar
Dr. Abdul Rahman Agha El Kinge
  • 0

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing approved reference biologic drug. In cancer supportive care, biosimilars have become increasingly important for managing various aspects of cancer treatment, including supportive therapies. One significant application of biosimilars in cancer supportive care is in the management of chemotherapy-induced neutropenia. Neutropenia, characterized by low levels of neutrophils (a type of white blood cell), is a common side effect of chemotherapy that can increase the risk of infections. Biosimilar versions of granulocyte colony-stimulating factors (G-CSFs), such as filgrastim and pegfilgrastim, are used to stimulate the production of neutrophils and reduce the duration and severity of neutropenia.

webinar
Dr. Abdul Rahman Agha El Kinge
  • 0

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing approved reference biologic drug. In cancer supportive care, biosimilars have become increasingly important for managing various aspects of cancer treatment, including supportive therapies. One significant application of biosimilars in cancer supportive care is in the management of chemotherapy-induced neutropenia. Neutropenia, characterized by low levels of neutrophils (a type of white blood cell), is a common side effect of chemotherapy that can increase the risk of infections. Biosimilar versions of granulocyte colony-stimulating factors (G-CSFs), such as filgrastim and pegfilgrastim, are used to stimulate the production of neutrophils and reduce the duration and severity of neutropenia.